Michael O'Riordan is the Managing Editor for TCTMD. He specializes in medicine and healthcare, focusing on medical reporting and advancements in treatment, particularly in cardiovascular diseases. Michael's work has been recognized with several awards, including a Digital Health Award in 2023, and he has been featured in TCTMD.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
Michael O'Riordan's articles predominantly cite data and cover topics related to cardiovascular disease, medical research, treatment options, and risk factors. He would likely be receptive to pitches offering insights from experts in the healthcare and pharmaceutical industry who can provide informed perspectives on new research findings, treatment developments, or changes in medical guidelines related to cardiovascular diseases.
Given his focus on citing data extensively in his coverage, he may appreciate pitches that offer access to proprietary or exclusive datasets relevant to the topics he covers. Additionally, sources with a deep understanding of scientific methodologies and clinical trial design could capture Michael's interest.
While there is no specified geographic focus for Michael's work, his articles appear internationally focused based on the subjects covered.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Michael O Riordan
Topline results announced today show gains in KCCQ and peak oxygen consumption—the full dataset is coming soon.
The default approach should be a staged procedure given the findings, which are in line with CULPRIT-SHOCK, says Gregg Stone.
The analysis, based on Medicare data, also showed women have higher risks of complications and early mortality than men.
It's going to be a busy 4 days in Paris, with 166 late-breaking studies and nearly 2,000 clinical cases to be presented.
With another 2 million diverse patients, including some from RCTs, the calculators were effective at identifying those at risk.
By: Michael O Riordan
In this high-risk population, those who had a prior PCI had higher event rates but benefited from aggressive LDL-lowering.
By: Michael O'Riordan
Ten years after revascularization, mortality rates were the same with either PCI or surgery in this patient subset.
By: Michael O'Riordan
The totality of data suggests that routine PCI prior to TAVI is not warranted in the majority of cases, a meta-analysis shows.
The rate of target lesion failure with Bioadaptor was just 2.8%, which astounded many operators.
By: Michael O'Riordan
The hemodynamic substudy is an attempt to understand why Impella didn’t benefit high-risk PCI patients.
